OSE Immunotherapeutics SA (LON:0RAD)

London flag London · Delayed Price · Currency is GBP · Price in EUR
5.93
-0.23 (-3.66%)
At close: Sep 12, 2025
-3.66%
Market Cap112.54M
Revenue (ttm)69.00M
Net Income (ttm)30.97M
Shares Outn/a
EPS (ttm)1.21
PE Ratio3.63
Forward PE6.53
Dividendn/a
Ex-Dividend Daten/a
Volume10
Average Volume582
Open5.92
Previous Close6.16
Day's Range5.92 - 5.93
52-Week Range4.82 - 11.22
Beta0.96
RSI37.55
Earnings DateSep 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 64
Stock Exchange London Stock Exchange
Ticker Symbol 0RAD
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.